[Federal Register Volume 79, Number 148 (Friday, August 1, 2014)]
[Notices]
[Page 44774]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-18173]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case:
    Jun Fu, Ph.D., University of Texas MD Anderson Cancer Center: Based 
on the Respondent's admission, the report of an inquiry conducted by 
the University of Texas MD Anderson Cancer Center (MDACC), and analysis 
conducted by ORI in its oversight review, ORI found that Dr. Jun Fu, 
former Postdoctoral Fellow, Department of Neuro-Oncology, MDACC, 
engaged in research misconduct in research supported by National Cancer 
Institute (NCI), National Institutes of Health (NIH), grants CA56041 
and CA127001.
    The Respondent has admitted to knowingly and intentionally 
falsifying Figure 8a in the following publication:
     ``Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle 
regulators to ablate Olig2-positive glioma tumor-initiating cells.'' 
Cancer Res. 73(10):3062-74, 2013 May 15.
    Specifically, the Respondent falsified survival times of mice to 
show that NVP-HSP990 prolonged survival rates in glioblastoma tumor 
bearing mice when experimental data were incomplete and unusable.
    As a result of its inquiry, MDACC has recommended that the senior 
author of this paper take any appropriate steps with the journal to 
correct the scientific literature.
    Dr. Fu has entered into a Voluntary Settlement Agreement 
(Agreement) and has voluntarily agreed for a period of two (2) years, 
beginning on July 15, 2014:
    (1) To have his research supervised; Respondent agrees that prior 
to the submission of an application for U.S. Public Health Service 
(PHS) support for a research project on which the Respondent's 
participation is proposed and prior to Respondent's participation in 
any capacity on PHS-supported research, Respondent shall ensure that a 
plan for supervision of Respondent's duties is submitted to ORI for 
approval; the supervision plan must be designed to ensure the 
scientific integrity of Respondent's research; Respondent agrees that 
he shall not participate in any PHS-supported research until such a 
supervision plan is submitted to and approved by ORI; Respondent agrees 
to maintain responsibility for compliance with the agreed upon 
supervision plan;
    (2) that any institution employing him shall submit, in conjunction 
with each application for PHS funds, or report, manuscript, or abstract 
involving PHS-supported research in which Respondent is involved, a 
certification to ORI that the data provided by Respondent are based on 
actual experiments or are otherwise legitimately derived and that the 
data, procedures, and methodology are accurately reported in the 
application, report, manuscript, or abstract; and
    (3) to exclude himself voluntarily from serving in any advisory 
capacity to PHS including, but not limited to, service on any PHS 
advisory committee, board, and/or peer review committee, or as a 
consultant.

FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research 
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 
453-8800.

Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2014-18173 Filed 7-31-14; 8:45 am]
BILLING CODE 4150-31-P